CD8 Antibody (MCD8): sc-51735
- CD8 Antibody (MCD8) is a mouse monoclonal IgG1, cited in 2 publications, provided at 100 µg/ml
- raised against CD8 of human origin
- recommended for detection of CD8 of human origin by IF, IHC(P) and FCM
- available conjugated to phycoerythrin for IF, IHC(P) and FCM
- See CD8 (32-M4): sc-1177 for CD8 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CD8 Antibody (MCD8). This work is in progress.
CD8 Antibody (MCD8) is a mouse monoclonal IgG1 antibody that detects CD8 protein of human origin by immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). Anti-CD8 antibody (MCD8) is available in both conjugated and non-conjugated forms, providing versatility for various experimental needs. CD8 protein, also known as Leu 2 or T8, is a crucial cell surface glycoprotein that forms a two-chain complex, either as αα or αβ, which interacts with class I major histocompatibility complex (MHC) molecules presented by antigen-presenting cells. This interaction is vital for the immune response, as CD8 plays a significant role in facilitating antigen recognition by the T cell receptor (TCR) and enhancing the strength of TCR-antigen interactions. Additionally, CD8-expressing T cells are essential for the cytotoxic response against infected or malignant cells, and may also contribute to the maintenance of low levels of HIV expression in infected individuals. CD8′s ability to strengthen TCR signaling underscores its importance in adaptive immunity, making CD8 (MCD8) monoclonal antibody an invaluable tool for researchers studying T cell function and immune responses.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD8 Antibody (MCD8) References:
- CD8+ T-cell immunity orchestrated by iNKT cells. | Qin, Y., et al. 2022. Front Immunol. 13: 1109347. PMID: 36741397
- PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion. | Hope, JL., et al. 2023. Cell Rep. 42: 112436. PMID: 37115668
- Insights into phenotypic and functional CD8+ TRM heterogeneity. | Heeg, M. and Goldrath, AW. 2023. Immunol Rev. 316: 8-22. PMID: 37191051
- Elderly CD8+ T cells in the focus for immunotherapeutic approaches. | Lis, A. and Zöphel, D. 2023. Aging (Albany NY). 15: 3899-3900. PMID: 37204431
- Quantitating CD8+ T cell memory development. | Nizharadze, T., et al. 2023. Trends Immunol. 44: 519-529. PMID: 37277233
- CD8+ T cells in brain injury and neurodegeneration. | Zhang, Z., et al. 2023. Front Cell Neurosci. 17: 1281763. PMID: 38077952
- CD8+ T cell-based cancer immunotherapy. | Chen, Y., et al. 2024. J Transl Med. 22: 394. PMID: 38685033
- Antitumor progenitor exhausted CD8+ T cells are sustained by TCR engagement. | Lan, X., et al. 2024. Nat Immunol. 25: 1046-1058. PMID: 38816618
- Stem-like CD8+ T cells in cancer. | Steiner, C., et al. 2024. Front Immunol. 15: 1426418. PMID: 39211052
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD8 Antibody (MCD8) | sc-51735 | 100 µg/ml | $322.00 | |||
CD8 Antibody (MCD8) PE | sc-51735 PE | 100 tests in 2 ml | $349.00 |